#Canada #Toronto #biotechnology #AmacaThera #AmacaGel

AmacaThera's Latest Collaboration Marks a New Era

In a significant move for the biotechnology sector, AmacaThera, a Toronto-based clinical-stage biotech firm, has announced a strategic collaboration with a renowned global pharmaceutical company. The primary goal of this partnership is to develop a groundbreaking long-acting biologic medication that requires a single injection. This innovative solution will harness AmacaThera's proprietary hydrogel delivery platform, known as AmacaGel™.

The announcement was made on April 8, 2025, during a press release highlighting the potential of this collaboration. AmacaThera's Chief Scientific Officer, Dr. Molly Shoichet, expressed enthusiasm for the project, emphasizing the synergy between the two organizations and their shared commitment to medical innovation. "This partnership allows us to utilize AmacaThera's extensive expertise in drug delivery to ensure the success of new biologic treatments," she stated.

Unique Drug Delivery Technology

AmacaGel™ is a cutting-edge hydrogel formulation that has been rigorously tested in both laboratory settings and human trials, particularly in association with therapeutic agents ranging from small molecules to biologics and stem cells. The platform's unique characteristic lies in its ability to release therapeutic agents over an extended period, significantly enhancing patient outcomes by reducing systemic side effects.

The partnership is co-funded by both organizations, which allows them to pool their complementary resources and speed up the development timeline for this innovative biologic treatment. Notably, the collaboration follows the successful completion of a Phase 1 clinical trial involving human subjects, which evaluated the effects of AmacaGel™ combined with a local anesthetic. This study yielded crucial data that confirm the platform's effectiveness in integrating with therapeutic payloads, setting a solid foundation for the upcoming joint project.

The Advantages of Hydrogel Technology

Mike Cooke, AmacaThera's CEO, remarked on the importance of this partnership, stating, "This collaboration builds on our manufacturing expertise and the human data we've gathered through our hydrogel platform. It enables us to develop effective solutions to address the challenges inherent in injectable products efficiently."

He further elaborated on what sets AmacaGel™ apart from other hydrogel technologies: its broad compatibility with various drug modalities, simple manufacturing processes, scalability, cost-effectiveness, and the robust data generated from human studies. These factors position AmacaThera as a leader in the biopharmaceutical landscape, addressing pressing healthcare needs.

Industry Support and Collaboration

Facilitated by CQDM's Connect-Pharma series, this partnership exemplifies how Canadian companies and academic institutions can connect with major global pharmaceutical firms. The CQDM serves as a non-profit consortium dedicated to fostering innovation and collaborative research within the biopharmaceutical sector. Notably, Raphael Hofstein, a board member at CQDM, highlighted the industry's trust in AmacaThera's hydrogel platform, reflecting its potential to leave a lasting impact.

Mark Steedman, CQDM's Senior Director of Business Development, expressed enthusiasm for the project, believing that the low-risk nature of AmacaThera’s technology will allow for rapid advancement and data generation.

About AmacaThera

AmacaThera is at the forefront of biotechnology, specializing in hydrogel formulations tailored for prolonged drug release. Their flagship platform, AmacaGel™, is designed to meet significant challenges in therapeutic administration, ultimately leading to improved patient outcomes. The company targets key therapeutic areas such as pain management and oncology, making strides to enhance the efficacy and safety of medical treatments.

With the backing of robust technological advancements and strategic partnerships, AmacaThera is poised to play a critical role in shaping the future of drug delivery and biopharmaceutical innovation. For more information about AmacaThera and their groundbreaking work, visit their website at www.amacathera.com.

About CQDM

CQDM, or the Consortium of Research and Development in Biopharmaceuticals, is a non-profit consortium that seeks to accelerate the application of innovative technologies within the biopharmaceutical industry. Through multi-party collaborations, CQDM aims to address unmet medical needs while generating significant economic benefits for the Canadian and Quebec economies. For more insights on CQDM's initiatives, visit their website at www.cqdm.org.